Galapagos NV (GLPG)
NASDAQ: GLPG · IEX Real-Time Price · USD
25.34
+0.33 (1.32%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Galapagos NV Revenue
Revenue in the quarter ending March 31, 2024 was $67.86M, a -137.76% decrease year-over-year. In the year 2023, Galapagos NV had annual revenue of $266.36M with 3.78% growth.
Revenue (ttm)
$266.36M
Revenue Growth
+3.78%
P/S Ratio
n/a
Revenue / Employee
$237,186
Employees
1,123
Market Cap
1.67B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.36M | 9.71M | 3.78% |
Dec 31, 2022 | 256.65M | -9.70M | -3.64% |
Dec 31, 2021 | 266.35M | -316.65M | -54.31% |
Dec 31, 2020 | 582.99M | -355.10M | -37.85% |
Dec 31, 2019 | 938.09M | 584.45M | 165.27% |
Dec 31, 2018 | 353.64M | 166.53M | 89.00% |
Dec 31, 2017 | 187.11M | 27.55M | 17.27% |
Dec 31, 2016 | 159.56M | 93.76M | 142.50% |
Dec 31, 2015 | 65.80M | -43.12M | -39.59% |
Dec 31, 2014 | 108.92M | -23.88M | -17.98% |
Dec 31, 2013 | 132.80M | 11.15M | 9.16% |
Dec 31, 2012 | 121.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
National HealthCare | 1.17B |
Harmony Biosciences Holdings | 617.51M |
Veracyte | 375.47M |
Zai Lab | 291.07M |
Mirum Pharmaceuticals | 224.00M |
Arvinas | 71.30M |
GLPG News
- 18 days ago - Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 - GlobeNewsWire
- 4 weeks ago - Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications - GlobeNewsWire
- 4 weeks ago - Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications - Newsfile Corp
- 6 weeks ago - Galapagos creates new subscription right plans - GlobeNewsWire
- 6 weeks ago - Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S. - GlobeNewsWire
- 2 months ago - Galapagos reports first quarter 2024 financial results - GlobeNewsWire
- 2 months ago - Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 - GlobeNewsWire
- 3 months ago - Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 - GlobeNewsWire